Pay in 4 interest-free payments of $6.94 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Orforglipron Maintains Weight Loss in Patients Switching from Semaglutide or Tirzepatide Orforglipron has met the primary and all key secondary endpoints in the phase 3 ATTAIN-MAINTAIN trial by providing superior weight maintenance compared to placebo in patients enrolled from the phase 3 SURMOUNT-5 trial, as announced by parent company Eli Lilly and Company on December 18, 2025
It is derived from the 176-191 region of human growth hormone
Caution: If you have any of these conditions, consult your healthcare provider before considering treatment
In addition, clinicians must consider comorbid conditions
Health Savings Accounts and Flexible Spending Accounts can be used to pay for prescription semaglutide since it is a medical treatment
Rothman, K
US$ 22.60
US$ 25.44
US$ 23.28
US$ 23.59
US$ 25.48
US$ 25.88
US$ 27.01
